RET and thyroid gland carcinoma: In addition to the search for exact matches, the search for general mutations in RET as a biomarker identifies a study investigating Selpercatinib for patients with thyroid cancer, which was classified with a sensitive response and with evidence level 1, indicating support by at least one well-powered, controlled clinical study (Fig. 2C, yellow box).